

1 **Most of *Staphylococcus aureus* and *Pseudomonas aeruginosa* co-infecting**
2 **isolates coexist, a condition that may impact clinical outcomes in Cystic**
3 **Fibrosis patients.**

4

5 Paul Briaud ^{a,*} (ORCID 0000-0001-7530-6803), Sylvère Bastien ^{a,*} (ORCID 0000-0002-3687-
6 8646), Laura Camus^a (ORCID 0000-0003-1335-8901), Marie Boyadjian^b, Philippe Reix^b
7 (ORCID 0000-0002-9192-8335), Catherine Mainguy^b, François Vandenesch ^{a,c} (ORCID 0000-
8 0001-9412-7106), Anne Doléans-Jordheim^c (ORCID 0000-0003-4985-3955) and Karen
9 Moreau^{a,#} (ORCID 0000-0001-6297-3543).

10

11 ^a CIRI, Centre International de Recherche en Infectiologie, Université de Lyon; Inserm U1111;
12 Ecole Normale Supérieure de Lyon; Université Lyon 1 ; CNRS, UMR5308; Lyon, France

13 ^b Pediatric Pulmonology Department, Hôpital Femme-Mère-Enfant, Hospices civils de Lyon,
14 UMR5558, Lyon, France.

15 ^c Institut des agents infectieux, Hospices Civils de Lyon, Lyon, France.

16

17 Running title: Coexistence of *S. aureus* and *P. aeruginosa* in CF

18 #Address correspondence to karen.moreau@univ-lyon1.fr

19 * PB and SB contributed equally to this work. Author order was determined on the basis of lab
20 position.

21

22

23 **Abstract:**

24

25 *Staphylococcus aureus* (SA) is the major colonizer of the lung of cystic fibrosis (CF) patient
26 during childhood and adolescence. As patient aged, the prevalence of SA decreases and
27 *Pseudomonas aeruginosa* (PA) becomes the major pathogen infecting adult lungs. Nonetheless,
28 SA remains significant and patients harbouring both SA and PA are frequently found in
29 worldwide cohort. Impact of coinfection remains controversial. Furthermore, co-infecting
30 isolates may compete or coexist. The aim of this study was to analyse if co-infection and
31 coexistence of SA and PA could lead to worse clinical outcomes. The clinical and
32 bacteriological data of 212 Lyon CF patients were collected retrospectively, and patients were
33 ranked into three groups, SA only (n=112), PA only (n=48) or SA plus PA (n=52). In addition,
34 SA and PA isolates from co-infecting patients were tested *in vitro* to define their interaction
35 profile. Sixty five percent (n=34) of SA/PA pairs coexist. Using univariate and multivariate
36 analysis, we confirm that SA patients have a clinical condition less severe than others, and PA
37 induce a poor outcome independently of the presence of SA. FEV1 is lower in patients infected
38 by competition strain pairs than in those infected by coexisting strain pairs compared to SA
39 mono-infection. Coexistence between SA and PA may be an important step in the natural
40 history of lung bacterial colonization within CF patients.

41

42

43 **Keywords:** Cystic Fibrosis, infection, *Staphylococcus aureus*, *Pseudomonas aeruginosa*,
44 clinical outcome.

45

46 **Introduction:**

47

48 Cystic fibrosis (CF) is the most common genetic disease among Caucasian population that
49 affects multiple organs and causes various complications associated with patient death such as
50 cystic fibrosis liver disease (1) (CFLD) or cystic fibrosis related diabetes (2) (CFRD) (1, 2).
51 However, the first cause of morbidity and mortality in CF remains the progressive decrease in
52 pulmonary function leading to an obstructive syndrome (3). This decline is generally due to the
53 continuous inflammation provoked by polymicrobial infections (3).

54 The main clinically significant bacteria are *Staphylococcus aureus* (SA) and *Pseudomonas*
55 *aeruginosa* (PA). SA infection occurs early in children and affects up to 80% of patients aged
56 5-19 years [4]. In early childhood, SA infection is responsible for increasing inflammatory
57 markers [5,6] and in adolescence, patients with high SA density in throat swabs present
58 deterioration of lung function [7]. However, despite the implication of SA in worse clinical
59 status, PA, which becomes the dominant pathogen of the respiratory tract in adulthood [4] (up
60 to 60% of patients > 18 years), remains traditionally the most feared pathogen due to its strong
61 association with most severe clinical outcomes, such as a more robust inflammation, an increase
62 in the number of exacerbations and a decrease in forced expiratory volume in one second
63 (FEV1) [8-11].

64 Even if SA colonization decreases as patients aging, SA infection concerns more than 30% of
65 CF adults (4). Among these cases, co-infection by PA and SA remains significant (5). However,
66 it is difficult to determine whether this co-infection is a transitional stage between SA alone and
67 PA alone or whether permanent co-infections with these two bacteria exist. Several *in vitro*
68 studies deciphered the relationships between SA and PA in a context of pulmonary co-infection
69 (6–10). According to recent studies, an evolution occurs regarding SA and PA clinical isolates
70 interaction. PA early-colonizing isolates show a strong antagonism towards SA strains (7, 8)

71 especially by producing anti-staphylococcal compounds, leading to a competition state (10).
72 However, PA isolated from chronic lung infection lack this competitiveness and SA succeeds
73 to coexist durably with PA (6, 9, 11). In this way, we previously demonstrated that in this
74 context of coexistence without antagonism, the two bacteria may cooperate to persist more
75 easily in lungs (Briaud *et al.*, 2019).

76 Only few studies investigated the impact of SA-PA co-infection and clinical outcomes. In
77 addition, none of them considered the interaction state (competition vs coexistence) between
78 SA-PA. So far, available data have shown conflicting results on the link between SA-PA co-
79 colonization and clinical outcomes. Ahlgren *et al.*, did not find a significant clinical difference
80 in adult patients co-colonized with SA plus PA compared to patient colonized solely by PA
81 (12). Two studies highlighted a higher respiratory decline and rate of hospital admission for
82 patients infected by PA alone in comparison with patients co-infected by SA-PA or by SA alone
83 (5, 13). Finally, other studies reported that SA-PA co-infection is associated with a worse
84 clinical outcome (14–17).

85 The aim of the study was to better characterize (i) co-infected patients with demographic data
86 (age, BMI, gender) and (ii) the interaction state (competition or coexistence) between the two
87 bacterial species. We also examined the consequence of SA-PA co-infection and SA-PA
88 interaction state (competition vs coexistence) on pulmonary functions (FEV1%) and clinical
89 outcomes (e.g. number of exacerbations, number of hospitalization). By computing
90 demographic and clinical data with pulmonary infectious status, we gain more information
91 about the impact of SA and PA infections and interactions in CF patient's health.

92

93 **Materials and Methods:**

94

95 **Patients:**

96 The clinical and bacteriological data of CF patients supervised at the two CF Centers in Lyon,
97 France, (CRCM: Centre de Ressources et de Compétences de la Mucoviscidose) were collected
98 from February 2017 to August 2018.

99 The inclusion criterion was a stable microbiological status for SA and /or PA colonization,
100 defined by the following criteria: i) at least three respiratory samples collected for each patient
101 throughout the period considered (ii) at least two months between two successive samples (iii)
102 all samples collected during the study for a patient had the same status with respect to the
103 presence of SA and / or PA. The patients who did not match the criteria, or who were not co-
104 colonized by SA or PA were excluded.

105 This study was submitted to the Ethics Committee of the Hospice Civil de Lyon (HCL) and
106 registered under CNIL No 17-216. All patients were informed of the study and did not oppose
107 to the use of their data.

108

109 **Clinical data gathering:**

110 Clinical data were extracted from computerized medical files (Easily®). Data collected were:
111 gender, age at the time of the last sampling, CFTR genotype classified between severe and
112 moderate genotype regardless of clinical severity (5, 18), pancreatic insufficiency defined by a
113 faecal elastase < 200µg/g, CF-related diabetes (CFRD) or a carbohydrate intolerance, cirrhosis,
114 an oral or enteral supplementation and/or an undernourishment (defined as a body mass index
115 (BMI) (weight/height^2) lower than 17kg/m² in an adult and -2 standard deviations (SD) in a
116 child according to the gender and age). The pulmonary function was defined by the FEV1
117 expressed as a percentage of the predicted value (%pred). We also gathered the number of
118 hospitalizations, the length of hospital stays and the number of exacerbations during the 9
119 months preceding the last sample.

120

121 **Microbiology:**

122 The microbiological composition of each respiratory sample was determined by the Institute
123 for Infectious Agent, HCL. The interaction state (coexistence or competition) of SA-PA pairs
124 was defined by agar competition assay as previously described (Briaud *et al.*, 2019). Briefly,
125 SA and PA isolates recovered from co-infected patient's expectorations were cultured in 10ml
126 of BHI, at 37°C, 200 rpm. From overnight cultures, SA and PA suspensions were diluted to
127 $OD_{600nm}=0.5$. Then, 100 μ L of SA suspension was spread uniformly onto trypticase soy agar
128 (TSA) plates. After a drying time, 5 μ l of PA suspension were spotted at the centre of the plates.
129 The plates were incubated at 37°C for 24 hours. The competitive phenotype was characterized
130 by an inhibition halo of SA growth. In absence of inhibition halo, isolates were defined in
131 coexistence.

132

133 Based on these microbiological analyses, the patients were categorized into four groups: (i) SA
134 alone, (ii) PA alone, (iii) or SA-PA in competition, and (iv) SA-PA in coexistence.

135

136 **Statistical analysis:**

137 Two different analyses were performed using the same process: (i) SA vs PA vs SA+PA, and
138 (ii) SA vs PA vs SA+PA in coexistence vs SA+PA in competition.

139 Factor Analysis of Mixed Data (FAMD) was used for initial data screen. Then, univariate
140 analysis was done to determine significant differences between groups. For continuous
141 variables (age, BMI, FEV1, number of hospitalizations, length of hospitalization and number
142 of exacerbation), Kruskal-Wallis tests were used to identify whether a population was different
143 from the others. Afterward, to individually test each pair of populations from significant
144 Kruskal-Wallis tests, a Mann-Whitney Wilcoxon tests was used. Fisher's exact tests were
145 performed to compare categorical variables (CFTR genotype, gender, Denutrition, pancreatic

146 insufficiency, CFRD, liver cirrhosis, enteral nutrition and food supply). For multiple
147 comparisons, tests were corrected by a Bonferroni method and statistical significance was set
148 with a q-value threshold at 0.05. Finally, a multinomial log-linear model (nnet package (19))
149 was used to determine significant associations between infectious status groups and variables
150 retained by Akaike information criterion (AIC) (20). The AIC analysis was performed in order
151 to identify the smallest and fittest set of variables describing our data. An adjusted odds-ratio
152 with 95% confidence interval was reported for each final variable. All analyses were performed
153 using R v3.5.3 (21).

154

155 **Results:**

156

157 **Clinical characteristics of patients**

158 Of the 655 CF patients monitored in Lyon hospitals, we selected patients with at least three
159 respiratory specimens with SA and / or PA during the study period. 276 patients were excluded
160 because of the absence of the three required samples. Sixty-five patients had neither SA nor PA
161 infection. Finally, 48 and 54 patients were excluded because of unstable SA-PA co-colonization
162 during the period or the inability to assess their pulmonary function (age <4 years). Finally, 212
163 patients with CF were included in this study.

164 The cohort consisted of 124 adults and 88 children with a mean age of 21.70 years (range 4-
165 69). The male-female ratio was homogeneous with approximately 51.42% (n=109) of men.
166 About 80.66% (n=171) had a severe CFTR genotype and 41 patients had a moderate one.
167 During this period, 39.62% (n=84) had an exacerbation and 25.94% (n=55) of the patients were
168 hospitalized (Table S1).

169 The 212 patients were classified following their chronic bronchial colonization in 3 different
170 groups: SA alone, PA alone and SA+PA. Co-infected patients were split into 2 subclasses

171 (competition and coexistence) regarding the SA-PA interaction state determined by agar
172 competition assay (Table 1). Among the 212 patients, 52.83% (n=112) had chronic bronchial
173 colonization with SA, 22.64% (n=48) with PA and 24.53% (n=52) with SA+PA. Within the 52
174 co-infected patients, 65.38% (n=34) of SA and PA isolates presented a coexistence interaction
175 and 34.62% (n=18) presented a competition phenotype. Patients solely colonized with PA were
176 older (average of 32.02y) than co-infected patients (average of 23.38y) and themselves older
177 than patients colonized by SA (average of 16.49y) (Table 1). This is consistent with the natural
178 history of infections and international values (4).

179
180 We proceeded to a FAMD analysis to decipher the similarity and heterogeneity between patient
181 groups using both continuous and categorical variables. The two first retained axes accounted
182 for 39.47% of the total variance of the data (Fig. S1). Four variables contributed to the first axe:
183 number of exacerbations, number and days of hospitalization and FEV1. Age, BMI and not
184 having pancreatic insufficiency contributed to the second axe. The repartition of the 212
185 patients based on the two first dimensions overlapped between the 4 groups (Fig. S1). Patients
186 infected by SA were the most represented group and appeared to have clinical variable values
187 more homogeneous than other patients. On the contrary, patients co-infected in a coexistence
188 state seemed to have values with a greater heterogeneity (Fig. S1).

189

190 **Impact of the co-infection on CF patient clinical outcome**

191 In order to define whether co-infection was associated with poorer clinical outcome, we
192 compared three groups: patients infected with SA, patients infected with PA and patients co-
193 infected with SA-PA. Continuous variable analysis differentiated the 3 patient groups (Table
194 2). SA patients seemed to be younger than co-infected patients, themselves younger than PA
195 patients ($p<0.0001$). SA group stood out from others by lower BMI values (PA vs SA:

196 $p < 0.0001$, SA+PA vs SA: $p = 0.0074$), a smaller number of hospitalizations (PA vs SA:
197 $p = 0.0017$, SA+PA vs SA: $p = 0.0013$), a reduced length of hospitalizations (PA vs SA:
198 $p = 0.0011$, SA+PA vs SA: $p = 0.0010$), a lower number of exacerbations ($p < 0.0001$) and an
199 higher FEV1 ($p < 0.0001$). Co-infected and PA groups were not statistically different for number
200 of hospitalizations, length of hospitalizations, number of exacerbations and FEV1. Only age
201 ($p = 0.0012$) and BMI ($p = 0.029$) values were significantly different. For the analysis of
202 categorical variables, CFRD was only statistically significant between PA versus SA mono-
203 infected group ($p = 0.0031$) and co-infected patients versus SA ($p = 0.0169$) (Table S2).

204 To further investigate these results and to consider potential association between variables,
205 multinomial analysis with infection type as outcome was performed using age, BMI, FEV1,
206 number of exacerbations, number of hospitalizations, length of hospitalizations and CFRD
207 (Table 3). Analyse through AIC criteria removed the three last characteristics suggesting that
208 number and length of hospitalizations and CFRD could not be associated with infection type.
209 The final model demonstrated that patients infected with PA were more likely to have a high
210 BMI [OR (95% CI): 1.2662 (1.0313, 1.5545)], a higher number of exacerbations; [OR (95%
211 CI): 2.0282 (1.2559, 3.2755)] and lower FEV1 [OR (95% CI): 0.9612 (0.9355, 0.9877)] relative
212 to patients infected with SA (Table 3). The results were similar when the co-infected group was
213 compared to SA only [OR (95% CI): BMI: 1.2022 (1.0015, 1.4432); exacerbations: 2.1660
214 (1.3514, 3.4078); FEV1: 0.9701 (0.9478, 0.9930)]. Comparing SA-PA group versus PA group,
215 only age criteria was significant as co-infected patients were more likely to be younger than
216 PA-mono-infected patients [OR (95% CI): 0.9477 (0.9017, 0.9961)].

217

218 **Impact of the bacterial coexistence and competition within co-infected CF patients**

219 The second objective of this study was to determine whether the interaction profile between SA
220 and PA could affect patient clinical outcome. Thus, we compared the mono-infected groups

221 (SA only and PA only) with two co-infected groups: SA plus PA in coexistence and SA plus
222 PA in competition.

223 Using continuous variables, the comparison between coexistence and competition groups
224 showed no significant difference (Fig. 1). No statistical differences were also found between
225 PA mono-infected and either SA plus PA in coexistence or in competition. Compared to SA
226 groups, both SA plus PA interaction groups seemed to infect older patients (Coex. vs SA.:
227 $p=0.0057$; Comp. vs SA: $p=0.0243$) with a higher number of exacerbations (Coex. vs SA:
228 $p<0.0001$; Comp. vs SA: $p=0.0003$) and lower values of FEV1 (Coex. vs SA: $p<0.0001$; Comp.
229 vs SA: $p=0.0001$). However, it is important to notice that, for BMI, number of hospitalization
230 and length of hospitalization criteria, only coexistence group is significantly different from SA
231 groups (Fig. 1). So, coexistence group presented higher values of BMI ($p=0.0449$), higher
232 number of hospitalizations ($p=0.0043$) and longer stay of hospitalizations ($p=0.0026$) compared
233 to SA groups.

234 Considering categorical variables, none characteristics were statically significant between the
235 two types of interaction (Table S3). However, comparing SA group, there was higher number
236 of CFRD patients in the coexistence group ($p=0.0164$); such criteria was not significant when
237 SA group was compared to competition group.

238 Finally, multinomial analysis was performed using all significant characteristics from
239 univariate tests. The final predictors retained after analyses of deviance through AIC criteria
240 were BMI, supply of food, number of exacerbations and FEV1. A significant difference was
241 found between the two types of interaction in co-infected patients. The coexistence state group
242 was more likely to need food supply than the competition group [OR (95% CI): 0.2262 (0.0536,
243 0.9541)] (Table 4). As univariate results, multivariate analyses confirmed that patients co-
244 infected by either a coexisting SA-PA pair, or a competition pair had higher odds of having
245 more exacerbations than those infected only by SA [OR (95% CI): 2.2896 (1.3982, 3.7494):

246 1.9090 (1.0956, 3.3262) respectively]. Compared to SA group, the competition state group
247 seemed to have lower values of FEV1 [OR (95% CI): 0.9589 (0.9300, 0.9887)] whereas the
248 coexistence state group were more likely to have higher BMI [OR (95% CI): 1.2047 (1.0210,
249 1.4213)].

250

251 **Diabetes outcome and infectious status are not associated**

252 Additional multivariate analyses were performed concerning CFRD patients due to statistically
253 significant difference between groups when performing univariate analyses (Table S2 and
254 Table S3). First of all, a multinomial analysis was conducted with the entire variables (including
255 the infection status) and taking CFRD as outcome. Through the analyses of deviance conducted
256 by AIC criteria, the following variables were excluded from the multinomial analysis: sex, BMI,
257 undernourishment, enteral nutrition, cirrhosis, length of hospitalisation, number of
258 exacerbations, FEV1 and type of infection. Thus, all these variables were not associated to
259 CFRD and CFRD patients were not more likely to be infected by neither SA nor PA nor
260 coinfecting by SA plus PA. Five characteristics were conserved in the final model where odds
261 ratios and associated adjusted p-values were reported (Table 5). CF-related diabetes patients
262 were more likely to be older [OR (95% CI): 1.1013 (1.0543, 1.1504)], to need more food supply
263 [OR (95% CI): 3.0259 (1.2297, 7.4459)] and were more hospitalized [OR (95% CI): 2.1662
264 (1.5254, 3.0763)].

265

266 **Discussion**

267

268 Lungs of CF patients are colonized by multiple bacteria and several studies were conducted to
269 decipher the impact of these colonisations on the clinical outcomes. We focused our study on
270 the two major pathogens responsible for chronic colonization: *Staphylococcus aureus* and

271 *Pseudomonas aeruginosa*. There is no gold standard to define chronic colonization especially
272 for SA. For PA infection, Leeds criteria (22) are sometimes used and define ‘chronic’ when
273 more than 50% of the preceding 12 months were PA culture positive. This definition requires
274 frequent expectoration sampling. Furthermore, these criteria may lack sensitivity and are not
275 always considered by clinicians (23). Alternatively, PA serology appears to be a sensitive
276 criterion to classify PA infection, especially in non-expectorating children but is not always
277 available (24). In order to clearly study the impact of SA and/or PA infection, we focused on
278 stabilized infections. Therefore, we considered chronic colonization when at least 3 samples
279 over a 9-month period had the same colonization pattern. These criteria are close to the
280 definition of European Consensus Criteria for PA colonisation. However, this stringent method
281 led to the exclusion of 33% of our cohort; 10% of patients were also excluded due to a change
282 in colonization status during the period studied. Finally, in our study, 52.83% of the remaining
283 patients had SA chronic colonization, 22.64% PA chronic colonization and 24.53% had chronic
284 co-colonization with both bacteria. These data are consistent with previous studies (5, 25).

285 The first point of our study was to compare the impact of chronic colonization by SA alone, PA
286 alone and SA plus PA on clinical outcome of CF patients. Indeed, being able to evaluate (or
287 even predict) the risks that a patient incurs depending on the type of bacterium and/or on
288 bacterial associations (in particular between PA and another pathogen) that colonize the lungs,
289 remains one of the major challenges in the management of patients. Thus, identifying patients
290 with harmful bacterial associations would be of clinical interest as they have increased risks of
291 worse clinical outcome. These bacterial association could become a therapeutic priority and
292 could be eradicated by targeting, for example, one of the pathogens. Conversely, we could
293 speculate that co-infection between PA and another bacterium represents a milder step in the
294 disease evolution, probably an intermediate stage between SA alone and PA alone.

295 In our study, we did not observe any differences regarding clinical status between patients co-
296 infected by PA and SA and those infected by PA alone. This suggests that the SA plus PA
297 combination does not lead to over- or under morbidity compared to the presence of PA alone
298 in the lungs and that there is no addition of the effects of the two pathogens. As soon as PA
299 colonise the CF lungs, whether SA is present or not, the clinical condition of the patients appears
300 to deteriorate. This agrees with the study by Ahlgreen *et al.* [12] but disagree with others [5,14-
301 17,22]. Indeed, studies on large size cohort with no distinction concerning age, suggested that
302 PA mono-infected group was the most severe [5,22] unlike studies on smaller cohort focus on
303 childhood concluded that co-infected group had the worst clinical outcomes [14,15,17]. In our
304 study, we did not focus on specific age class due to the limited size of the cohort. The sizes of
305 the cohorts and the age class studied could explain these dissimilarities and should be
306 considered to analyse CF clinical outcome.

307 Our results showed that SA chronic colonization conducted to a higher FEV1 (85.87 ± 22.39),
308 less exacerbations (0.25 ± 0.69), a smaller number of hospitalizations (15.18% of SA patients)
309 and shorter stay (8.00 ± 6.10) than SA plus PA co-infection or PA alone. This result confirms
310 previous studies (12) showing that SA infection alone is a marker of milder disease comparing
311 to PA, with less exacerbation rate and highest clinical score. Moreover, Hubert *et al.* (5) pointed
312 out that co-infection by methicillin-susceptible SA (MSSA) and PA was more severe (lower
313 FEV1 and higher IV antibiotic courses in one year) than mono-infection by MSSA. In the same
314 way, Cios *et al.* (25) found that only MSSA group was milder comparing to co-infection group.
315 Notably, association between SA alone and milder disease was not observed with MRSA.
316 Indeed, MRSA was associated with higher hospitalization rate and re-hospitalization compared
317 to co-infection. The SA methicillin resistant status seems to be, at the opposite, a severity
318 marker of SA infection in CF patients. In our cohort, only 15 MRSA cases were reported. This
319 low case number was not enough to perform analyses and conclude about impact of methicillin-

320 resistance status on clinical outcomes. Further studies are required to figure out why MRSA -
321 per se or as a surrogate marker of other genetic determinants- negatively impact the clinical
322 outcome of CF patients. Moreover, other features of SA strains, such as the toxins production,
323 could complement this analysis to more accurately describe the impact of SA in CF population.
324
325 CFRD is a severe complication of CF and association with bacterial infection could be used as
326 a predictive marker of severity. CFRD seemed to be overrepresented in mono-infected PA
327 (29.17%) and coinfecting (25%) patients and under-represented in mono-infected SA patients
328 (8.04%). CFRD represented 16.98% of our total patients and was slightly higher to CFRD rate
329 in European population (26). Limoli *et al.* (16) showed that CFRD status was marginally
330 associated, with an higher odds ratio, with co-infection by both SA and PA [OR (95% CI): 1.90
331 in comparison to SA or PA mono-infection(0,99, 3,6)]. We did not confirm this result. Indeed,
332 our multivariate analysis demonstrate that CFDR was associated to the age of the patients [OR
333 (95% CI): 1.1013 (1.0543, 1.1504)]. As co-infected and PA infected patients are older than SA
334 patients, CFDR could be more represented in the two first groups. However, we cannot exclude
335 that the difference between the two studies can be explained by a lower number of patients in
336 our study.

337
338 The second objective of the present study was to evaluate the impact of the type of interaction
339 between SA and PA (competition or coexistence) on clinical outcomes. Among the 52 patients
340 co-colonized with SA and PA, 65.38% of strain pairs were in coexistent interaction and 34.61%
341 in competition. These competitive and coexistence status were already described (6–8, 11, 27,
342 28). However, this is the first time that the type of interaction was evaluated in a large number
343 of clinical isolates and we described that coexistence is the predominant interaction type in
344 chronically co-colonized patients.

345 It has been accepted and described for a long time that PA could suppress SA growth by several
346 mechanisms (10). These data led to the theory that PA colonization causes SA elimination into
347 lungs patients. In fact, in our cohort, 24% of patients are co-colonized, which is consistent with
348 other studies (5, 16). Moreover, SA-PA pairs from co-infected patients were mostly coexisting.
349 Thus, our study shows that in 34 patients, chronic co-colonization may be due, at least in part,
350 to the inability of PA to suppress SA. It has been well described that, in CF lungs, PA strains
351 evolve and adapt from virulent early-infecting strains to less-virulent late-infecting strains (6,
352 8). Stresses induced by the pulmonary environment (oxidative and osmotic), antibiotic
353 treatments, immune system and other bacteria species, constitutes selective pressure forces for
354 adaptive mutations selection (8, 11, 17). Virulence changes could also reduce the antagonistic
355 action of the PA isolates on SA (7, 8). However, of all the factors affecting PA's evolution to
356 the pulmonary environment, the role of SA on PA evolution remains to be explored.

357 Nonetheless, in the present study, we did not observe a different age between patients colonized
358 with coexisting isolates (23.24 ± 10.52) and patients colonized with competitive pairs ($23.67 \pm$
359 8.98). This suggests that there would be no link between adapted late-infecting strains and
360 coexistence. In order to clarify this point, longitudinal studies will be necessary to evaluate the
361 link between bacteria interaction status and isolates evolution.

362 How PA tolerance towards SA may contribute to worst clinical outcome is a point that has not
363 been explored before. Except for food supply through multinomial analyses, no significant
364 difference in clinical outcomes between patient with coexisting pairs and patients with
365 competitive pairs was observed. Nevertheless, compared to SA group, patients infected by
366 competition pair were more likely to have lower FEV1 than those infected by coexisting pair.

367 These results may suggest that competition isolates may induce a more severe disease. Several
368 quorum sensing dependent virulence factors are produced by competition PA strains such as
369 rhamnolipids and phenazines (10), that could trigger an higher inflammatory response and a

370 lower FEV1. On the contrary, coexisting PA strains lacking the production of virulence factors
371 could less damage the lung environment. The clinical outcome is therefore mainly due to the
372 genotype/phenotype of PA. However, as described previously, the PA adaptation is related to
373 many environmental factors, including the surrounding bacteria. Thus, in the coexistence
374 context, a current analysis of SA impact on PA transcriptome and growth phenotype suggests
375 that SA could favour PA persistence (Camus et al., in preparation), and then influence the
376 clinical evolution. A larger patient cohort would be necessary to evaluate the real impact of
377 coexistence state on clinical outcomes. Coexistence between SA and PA may be an important
378 step of lung bacterial colonization in CF patient, and preventing this phenomenon could
379 participate in an adapted or even personalized management of CF patients.

380

381 **Ethical statement**

382 All methods were carried out in accordance with relevant French guidelines and
383 regulations. This study was submitted to the Ethics Committee of the Hospices Civils de Lyon
384 (HCL) and registered under CNIL No 17-216.

385

386 **Acknowledgments.**

387 “Vaincre la mucoviscidose” and “Gregory Lemarchal” associations supported this work. P
388 Briaud was supported by French Ministry of Education and Research and L Camus was
389 supported by Fondation pour la Recherche Médicale (grant number ECO20170637499). We
390 thank Marie Verneret for technical support.

391

392 **Authors' contributions:**

393 PB, ADJ and KM contributed to conception and design of the study. PR, CM and FV
394 contributed to design of the study. PB and LC conducted the experiments. SB conducted and

395 analyzed all statistics. MB and ADJ collected the data. All authors contributed to manuscript
396 and approved the submitted version.
397 None of the authors have any conflict of interest to report.
398

399 **References:**

400

401 1. Debray D, Narkewicz M, Bodewes F, Colombo C, Housset C, Jonge H de, Jonker J, Kelly D, Ling
402 S, Poynard T, Sogni P, Trauner M, Witters P, Baumann U, Wilschanski M, Verkade H. 2017.
403 Cystic Fibrosis–related Liver Disease: Research Challenges and Future Perspectives. *J Pediatr*
404 *Gastroenterol Nutr* 65:443–448.

405 2. Brennan AL, Beynon J. 2015. Clinical updates in cystic fibrosis-related diabetes. *Semin Respir Crit*
406 *Care Med* 36:236–250.

407 3. Davis PB. 2006. Cystic Fibrosis Since 1938. *Am J Respir Crit Care Med* 173:475–482.

408 4. Zolin, Orenti, Naehrlich, van Rens. 2019. ECFS Patient Registry Annual Data Report 2017.

409 5. Hubert D, Réglier-Poupet H, Sermet-Gaudelus I, Ferroni A, Le Bourgeois M, Burgel P-R, Serreau
410 R, Dusser D, Poyart C, Coste J. 2013. Association between *Staphylococcus aureus* alone or
411 combined with *Pseudomonas aeruginosa* and the clinical condition of patients with cystic fibrosis.
412 *J Cyst Fibros* 12:497–503.

413 6. Limoli DH, Whitfield GB, Kitao T, Ivey ML, Davis MR, Grahl N, Hogan DA, Rahme LG, Howell
414 PL, O’Toole GA, Goldberg JB. 2017. *Pseudomonas aeruginosa* Alginate Overproduction
415 Promotes Coexistence with *Staphylococcus aureus* in a Model of Cystic Fibrosis Respiratory
416 Infection. *mBio* 8:e00186-17.

417 7. Baldan R, Cigana C, Testa F, Bianconi I, De Simone M, Pellin D, Di Serio C, Bragonzi A, Cirillo
418 DM. 2014. Adaptation of *Pseudomonas aeruginosa* in Cystic Fibrosis Airways Influences
419 Virulence of *Staphylococcus aureus* In Vitro and Murine Models of Co-Infection. *PLoS ONE*
420 9:e89614.

- 421 8. Michelsen CF, Christensen A-MJ, Bojer MS, Hoiby N, Ingmer H, Jelsbak L. 2014. *Staphylococcus*
422 *aureus* Alters Growth Activity, Autolysis, and Antibiotic Tolerance in a Human Host-Adapted
423 *Pseudomonas aeruginosa* Lineage. *J Bacteriol* 196:3903–3911.
- 424 9. Michelsen CF, Khademi SMH, Johansen HK, Ingmer H, Dorrestein PC, Jelsbak L. 2016. Evolution
425 of metabolic divergence in *Pseudomonas aeruginosa* during long-term infection facilitates a proto-
426 cooperative interspecies interaction. *ISME J* 10:1323–1336.
- 427 10. Hotterbeekx A, Kumar-Singh S, Goossens H, Malhotra-Kumar S. 2017. In vivo and In vitro
428 Interactions between *Pseudomonas aeruginosa* and *Staphylococcus* spp. *Front Cell Infect*
429 *Microbiol* 7.
- 430 11. Tognon M, Köhler T, Gdaniec BG, Hao Y, Lam JS, Beaume M, Luscher A, Buckling A, van Delden
431 C. 2017. Co-evolution with *Staphylococcus aureus* leads to lipopolysaccharide alterations in
432 *Pseudomonas aeruginosa*. *ISME J*.
- 433 12. Ahlgren HG, Benedetti A, Landry JS, Bernier J, Matouk E, Radzioch D, Lands LC, Rousseau S,
434 Nguyen D. 2015. Clinical outcomes associated with *Staphylococcus aureus* and *Pseudomonas*
435 *aeruginosa* airway infections in adult cystic fibrosis patients. *BMC Pulm Med* 15:67.
- 436 13. Cios K, Cohen B, Quittell LM, Liu J, Larson EL. 2019. Impact of colonizing organism in the
437 respiratory tract on the incidence, duration, and time between subsequent hospitalizations among
438 patients with cystic fibrosis. *Am J Infect Control* 47:750–754.
- 439 14. Sagel SD, Gibson RL, Emerson J, McNamara S, Burns JL, Wagener JS, Ramsey BW. 2009. Impact
440 of *Pseudomonas* and *Staphylococcus* Infection on Inflammation and Clinical Status in Young
441 Children with Cystic Fibrosis. *J Pediatr* 154:183-188.e3.
- 442 15. Gangell C, Gard S, Douglas T, Park J, de Klerk N, Keil T, Brennan S, Ranganathan S, Robins-
443 Browne R, Sly PD, AREST CF. 2011. Inflammatory responses to individual microorganisms in
444 the lungs of children with cystic fibrosis. *Clin Infect Dis Off Publ Infect Dis Soc Am* 53:425–432.

- 445 16. Limoli DH, Yang J, Khansaheb MK, Helfman B, Peng L, Stecenko AA, Goldberg JB. 2016.
446 Staphylococcus aureus and Pseudomonas aeruginosa co-infection is associated with cystic
447 fibrosis-related diabetes and poor clinical outcomes. *Eur J Clin Microbiol Infect Dis* 35:947–953.
- 448 17. Hudson VL, Wielinski CL, Regelman WE. 1993. Prognostic implications of initial oropharyngeal
449 bacterial flora in patients with cystic fibrosis diagnosed before the age of two years. *J Pediatr*
450 122:854–860.
- 451 18. Welsh MJ, Smith AE. 1993. Molecular mechanisms of CFTR chloride channel dysfunction in cystic
452 fibrosis. *Cell* 73:1251–1254.
- 453 19. William Venables. 2016. nnet: Feed-Forward Neural Networks and Multinomial Log-Linear
454 Models.
- 455 20. Akaike H. 1998. Information Theory and an Extension of the Maximum Likelihood Principle, p.
456 199–213. *In* Parzen, E, Tanabe, K, Kitagawa, G (eds.), *Selected Papers of Hirotugu Akaike*.
457 Springer New York, New York, NY.
- 458 21. R Core Team. 2018. R: A Language and Environment for Statistical Computing. R Foundation for
459 Statistical Computing, Vienna, Austria.
- 460 22. Lee TWR, Brownlee KG, Conway SP, Denton M, Littlewood JM. 2003. Evaluation of a new
461 definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. *J Cyst Fibros*
462 2:29–34.
- 463 23. Hoo ZH, Edenborough FP, Curley R, Prtak L, Dewar J, Allenby MI, Nightingale JA, Wildman MJ.
464 2018. Understanding Pseudomonas status among adults with cystic fibrosis: a real-world
465 comparison of the Leeds criteria against clinicians’ decision. *Eur J Clin Microbiol Infect Dis*
466 37:735–743.
- 467 24. Taccetti G, Denton M, Hayes K, Drevinek P, Sermet-Gaudelus I, Bilton D, Campana S, Dolce D,
468 Ferroni A, Héry-Arnaud G, Martin-Gomez M-T, Nash E, Pereira L, Pressler T, Tümmler B. 2019.

469 A critical review of definitions used to describe *Pseudomonas aeruginosa* microbiological status
470 in patients with cystic fibrosis for application in clinical trials. *J Cyst Fibros* S1569199319308677.

471 25. Cios K, Cohen B, Quittell LM, Liu J, Larson EL. 2019. Impact of colonizing organism in the
472 respiratory tract on the incidence, duration, and time between subsequent hospitalizations among
473 patients with cystic fibrosis. *Am J Infect Control* 47:750–754.

474 26. Kerem E, Viviani L, Zolin A, MacNeill S, Hatziagorou E, Ellemunter H, Drevinek P, Gulmans V,
475 Krivec U, Olesen H. 2014. Factors associated with FEV1 decline in cystic fibrosis: analysis of the
476 ECFS Patient Registry. *Eur Respir J* 43:125–133.

477 27. Cigana C, Bianconi I, Baldan R, De Simone M, Riva C, Sipione B, Rossi G, Cirillo DM, Bragonzi
478 A. 2017. *Staphylococcus aureus* impacts *Pseudomonas aeruginosa* chronic respiratory disease in
479 murine models. *J Infect Dis*.

480 28. Briaud P, Camus L, Bastien S, Doléans-Jordheim A, Vandenesch F, Moreau K. 2019. Coexistence
481 with *Pseudomonas aeruginosa* alters *Staphylococcus aureus* transcriptome, antibiotic resistance
482 and internalization into epithelial cells. *Sci Rep* 9:1–14.

483

484

485

486 Table 1: Clinical characteristics of CF patients according to their bacteriological status

487

	SA alone	PA alone	SA and PA		merge	p_value*
	(%)	(%)	competition	coexistence		
Number	112/212	48/212	18/52 (34.61)	34/52 (65.38)	52/212	
Age (years)	16.49 ± 8.77	32.02 ±	23.67 ± 8.98	23.24 ± 10.52	23.38 ±	<0.0001 ^a
≥18 years	45/112	42/48	14/18	23/34	37/52	
Sex, male	63/112	23/48	10/18	13/34	23/52	ns
Genotype						
Moderate	26/112	9/48	3/18	3/34	6/52	ns
Severe	86/112	39/48	15/18	31/34	46/52	
BMI (kg/m ²)	18.06 ± 2.68	20.74 ± 2.42	19.25 ± 2.56	19.71 ± 3.56	19.55 ±	<0.0001 ^a
Undernourishment	11/112	1/48	1/18	3/34	4/52	ns
Food supply	23/112	13/48	3/18	15/34	18/52	ns
Enteral nutrition	4/112	0/48	0/18	4/34	4/52	ns
Pancreatic	101/112	45/48	17/18	33/34	50/52	ns
CF-related diabetes	9/112	14/48	3/18	10/34	13/52	0.0007 ^b
Cirrhosis	6/112	2/48	0/18	1/34	1/52	ns
Hospitalizations during						
Number	17/112	18/48	6/18	14/34	20/52	0.0003 ^a
Length	8.00 ± 6.10	17.39 ±	7.33 ± 6.12	29.14 ± 27.39	22.60 ±	0.0002 ^a
Number of	0.25 ± 0.69	1.44 ± 1.37	1.28 ±	1.35 ±	1.33 ±	<0.0001 ^a
FEV1(% predicted)	85.87 ±	55.09 ±	59.72 ± 18.73	64.59 ± 21.79	62.90 ±	<0.0001 ^a

488 BMI: Body Mass Index

489 FEV1: Forced Expiratory Volume in one second

490 * P values from comparison between three groups: SA vs PA vs SA+PA (merge).

491 ^a P values from Kruskal-Wallis non-parametric test for comparison of the three groups (continuous
492 variables)

493 ^b P values from Fisher's exact test for comparison of the three groups (categorical variables)

494

495 Table 2: P-values for continuous variables comparisons between SA mono-infected (SA), PA
496 mono-infected (PA) and co-infected groups (SA+PA). Mann-Whitney Wilcoxon non-
497 parametric test corrected by a Bonferroni method was used.

498

	PA vs SA	SA+ PA vs SA	SA+PA vs PA
Age	<0.0001	<0.0001	0.0012
BMI	<0.0001	0.0074	0.029
Number of hospitalizations	0.0017	0.0013	ns
Length of hospitalization	0.0011	0.0010	ns
Number of exacerbations	<0.0001	<0.0001	ns
FEV1	<0.0001	<0.0001	ns

499

500

501 Table 3: Adjusted odds ratios of cystic fibrosis patients' infection status. Multinomial
 502 regression analyses were performed to study associations between the type of infection (SA
 503 mono-infected (SA), PA mono-infected (PA) and co-infected groups (SA+PA)) and clinical
 504 outcomes. Adjusted odds ratios with 95% confidence intervals (CI) are mentioned.
 505

	PA vs SA		SA+ PA vs SA		SA+PA vs PA	
	OR (95 % CI)	p_value	OR (95 % CI)	p_value	OR (95 % CI)	p_value
Age	-	0.1354	-	0.6767	0.9477 (0.9017, 0.9961)	0.0345
BMI	1.2662 (1.0313, 1.5545)	0.0242	1.2022 (1.0015, 1.4432)	0.0481	-	0.5913
Number of exacerbations	2.0282 (1.2559, 3.2755)	0.0038	2.1460 (1.3514, 3.4078)	0.0012	-	0.7298
FEV1	0.9612 (0.9355, 0.9877)	0.0043	0.9701 (0.9478, 0.9930)	0.0108	-	0.4947

506

507

508

509 Table 4: Adjusted odds ratios of cystic fibrosis patients' infection status. Multinomial
 510 regression analyses were performed to study associations between the type of infection (SA
 511 mono-infected (SA), PA mono-infected (PA) and co-infected groups in coexistence state
 512 (Coex.), or in competition state (Comp.)) and clinical outcomes. Adjusted odds ratios with 95%
 513 confidence intervals (CI) are mentioned.
 514

	Coex vs SA		Comp vs SA		Comp Vs Coex	
	OR (95 % CI)	p_value	OR (95 % CI)	p_value	OR (95 % CI)	p_value
BMI	1.2047 (1.0210, 1.4213)	0.0273	-	0.3199	-	0.4872
Food supply	-	0.0801	-	0.3609	0.2262 (0.0536, 0.9541)	0.0430
Number of exacerbations	2.2896 (1.3982, 3.7494)	0.0010	1.9090 (1.0956, 3.3262)	0.0228	-	0.4472
FEV1	-	0.0861	0.9589 (0.9300, 0.9887)	0.0072	-	0.1885


515

516

517 Table 5: Adjusted odds ratios of cystic fibrosis-related diabetes (CFRD) patients' infection
518 status. Multinomial regression analyses were performed to study associations between cystic
519 fibrosis-related diabetes (CFRD) and other clinical outcomes including infection type. Adjusted
520 odds ratios with 95% confidence intervals (CI) are mentioned.

	OR (95 % CI)	p_value
Age	1.1013 (1.0543, 1.1504)	<0.0001
Genotype	-	0.1022
Food supply	3.0259 (1.2297, 7.4459)	0.0160
Pancreatic insufficiency	-	0.8192
Number of hospitalizations	2.1662 (1.5254, 3.0763)	<0.0001

532
533
534
535
536
537
538



539

540 Fig 1: Comparison between SA mono-infected (SA), PA mono-infected (PA) and co-infected
541 groups in competition (Comp) or in coexistence (Coex). Mann-Whitney Wilcoxon non-
542 parametric test corrected by a Bonferroni method was used


543

544 **Supplementary data**

545

546

547



548 Fig. S1: Individual factor map from FAMD based on 212 patients using the two first principal
549 components. Patients are colored according to their infection type, SA mono-infected (red), PA
550 mono-infected (yellow), SA+PA coinfection in a competition state (blue), SA+PA coinfection
551 in a coexistence state (cyan). Associated eigenvalue plot is shown at the top right.

552

553 Table S1: Patients characteristics at the time of the study

Baseline characteristics	Numbers of patients	Mean \pm SD or Percentage
Age (years)	212	21.70 \pm 12.09
≥ 18 years	124/212	58.49%
Sex, male	109/212	51.42%
Genotype		
Moderate	41/212	19.34%
Severe	171/212	80.66%
BMI (kg/m ²)	212	19.03 \pm 2.97
Undernourishment	16/212	7.55%
Food supply	54/212	25.47%
Enteral nutrition	8/212	3.77%
Pancreatic sufficiency	16/212	7.55%
CF-related diabetes	36/212	16.98%
Cirrhosis	9/212	4.25%
Hospitalizations during study period	55/212	25.94%
Number		1.96 \pm 1.17
Length (days)		16.38 \pm 18.28
Exacerbations*	84	0.78 \pm 1.24
FEV1 (% predicted)	212	73.27 \pm 25.12

554 BMI: body mass index

555 FEV1: forced expiratory volume in one second

556 * Corresponding to total number of exacerbations

557 Table S2: P-values for categorical variables comparisons between *S. aureus* mono-infected
558 (SA), *P. aeruginosa* mono-infected (PA) and co-infected groups (SA+PA). Fisher's exact test
559 corrected with a Bonferroni method was used.

560

561

	PA vs SA	SA+ PA vs SA	SA+PA vs PA
Sex	-	-	-
Genotype	-	-	-
Undernourishment	-	-	-
Food supply	-	-	-
Enteral nutrition	-	-	-
Pancreatic sufficiency	-	-	-
CF-related diabetes	0.0031	0.0169	ns
Liver cirrhosis	-	-	-

562

563

564

565 Table S3: P-values for categorical variables comparisons between *S. aureus* mono-infected
566 (SA), *P. aeruginosa* mono-infected (PA), co-infected in a coexistence (Coex) state and co-
567 infected in a competition (Comp) state group.

568

	Coex vs SA	Comp vs SA	Coex vs PA	Comp vsPA	Comp. vs Coex
Sex	-	-	-	-	-
Genotype	-	-	-	-	-
Undernourishment	-	-	-	-	-
Food supply	ns	ns	ns	ns	ns
Enteral nutrition	-	-	-	-	-
Pancreatic insufficiency	-	-	-	-	-
CF-related diabetes	0.0164	ns	ns	ns	ns
Liver cirrhosis	-	-	-	-	-

569

570